Guggenheim Capital LLC Vir Biotechnology, Inc. Transaction History

Guggenheim Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.14 - $24.62 $68,138 - $183,542	7,455 Added 11.81%	70,606 $661,000
Q2 2023 Aug 11, 2023	BUY	$23.2 - $27.29 $250,026 - $294,104	10,777 Added 20.58%	63,151 $1.55 Million
Q1 2023 May 10, 2023	BUY	$22.26 - $30.85 $770,017 - $1.07 Million	34,592 Added 194.53%	52,374 $1.22 Million
Q4 2022 Feb 14, 2023	BUY	$19.96 - $28.22 $71,217 - $100,688	3,568 Added 25.1%	17,782 $450,000
Q3 2022 Nov 14, 2022	SELL	$18.26 - $31.1 $289,840 - $493,650	-15,873 Reduced 52.76%	14,214 $274,000
Q2 2022 Aug 15, 2022	BUY	$19.08 - $26.7 $574,059 - $803,322	30,087 New	30,087 $766,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.